Stockreport
Amgen Inc. (AMGN): A Bull Case Theory [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Amgen Inc.'s share was trading at $325.54 as of January 12th. AMGN's trailing and forward P/E were 25.18 and 14.79 respectively according to Yahoo Finance. Copyright: lightwise / 123RF Stock Photo Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide and has seen a steady recovery in 2025, with shares recently trading at $320.20 — near their yearly high of $335.88 and well above the $253.30 low earlier in the year. The stock spent much of last year lagging below $290, but patient investors were rewarded after a strong Q3 earnings report reignited momentum. Amgen delivered a 12% year-over-year revenue increase, surpassing prior market expectations that had forecast stagnation. At the start of the year, 12 of its drugs were growing sales at double-digit rates; by Q3, that number had climbed to 16, underscoring the breadth of its expanding portfolio. The market, however, still views Amgen primarily as a stable dividend play, underestimating its a
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Erythropoietin Stimulating Agents Market Size to Reach USD 16.81 Billion by 2033, Driven by Rising chronic kidney disease and Chemotherapy-Induced Anemia Cases – SNS Insider [Yahoo! Finance][Yahoo! Finance]
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Royal Bank Of Canada from $330.00 to $335.00. They now have an "outperform" rating on the stock.[MarketBeat]
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $400.00 to $403.00. They now have a "buy" rating on the stock.[MarketBeat]
- Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss [CNBC][CNBC]
- Amgen CEO Bob Bradway goes one-on-one with Jim Cramer [CNBC][CNBC]
- More
AMGN
SEC Filings
SEC Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/13/25 - Form 4
- AMGN's page on the SEC website
- More